Completed PHASE3 INTERVENTIONAL NCT00088478

Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia

A Double-Blind, Randomized Study Comparing Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia

Sponsor: Eli Lilly and Company

Conditions Schizophrenia

Interventions Intramuscular Olanzapine Depot Placebo

Updated 6 times since 2017 Last updated: Jun 11, 2007 Started: Jun 30, 2004 Completion: Apr 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00088478, this PHASE3 trial focuses on Schizophrenia and remains completed. Sponsored by Eli Lilly and Company, it has been updated 6 times since 2004, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jun 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Beachwood, United States , Bradenton, United States , Chagrin Falls, United States , Chicago, United States , Clementon, United States , Columbia, United States , Denver, United States , Hoffman Estates, United States , Honolulu, United States and 26 more locations